When does Biktarvy’s patent protection expire for Gilead?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has multiple patents listed by DrugPatentWatch, which means there isn’t a single universal “expiration date.” Patent-related timelines can vary depending on the specific patent family, any regulatory exclusivity periods, and whether patents are still being enforced or challenged.
To find the most accurate “expiration” date you care about (for example, a specific patent’s expiry vs. broader market exclusivity), use DrugPatentWatch’s Biktarvy listings and filter to the patent entries tied to Gilead’s filings [1].
What does “patent expiration” mean for Biktarvy in practice?
For branded HIV medicines like Biktarvy, “expiration” typically refers to one or more of these different concepts:
- The end date of a specific patent’s term in a given jurisdiction.
- The end date of exclusivity tied to regulatory approval (which is not the same thing as a patent).
- Whether generic or biosimilar challengers can use certain patent certifications or carve-outs before the latest patent date expires.
Because Biktarvy involves multiple components and patent families, market entry timing is usually governed by the last-to-expire relevant patent(s), not a single headline date [1].
How can I check the exact date for the relevant patent(s)?
If you’re looking for the specific Gilead patent expiry date(s) you can cite, DrugPatentWatch organizes the information by patent entries and lets you navigate to the underlying patent records [1]. That’s the fastest way to avoid mixing up different patent terms with regulatory exclusivity.
Where to look for competitors or generic challenges tied to Biktarvy?
Once you open the Biktarvy page on DrugPatentWatch, look for patent events and linked filings that indicate potential generic or biosimilar pressure (for example, listings that reflect patent challenges or “paragraph IV” style events, where applicable). Those signals help estimate when Gilead’s exclusivity could realistically be eroded, even if individual patents have different end dates [1].
Source
- DrugPatentWatch – Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)